December 26, 2021
3 min watch
Save
VIDEO: Expert spotlights important takeaway from pacritinib safety analysis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aaron T. Gerds, MD, MS, speaks with Healio about the safety of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
The retrospective analysis, presented at ASH Annual Meeting and Exposition, pooled data from the phase two dosefinding PAC203 study and phase 3 PERSIST-2 study.
“The key piece here is that sick patients are sick, and that includes patients who are thrombocytopenic who have myelofibrosis,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.
Reference
- Mascarenhas J, et al. Abstract 3640. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.